Skip to main content

Table 3 Prevalence of persistent pain, according to the treatments performed

From: Prevalence of persistent pain after breast cancer treatment by detection mode among participants in population-based screening programs

  Persistent paina  
  N (%) P-value
Surgery (n = 1043)   
 Radical (n = 224) 27 (12.1) 0.693
 Conservative (n = 819) 91 (11.1)  
Axillary treatmentb (n = 983)   <0.01
 Only SLNB (n = 268) 18 (6.7)  
 ALND (n = 715) 98 (13.7)  
Neoadjuvant therapy (n = 1045)   0.090
 No (n = 936) 111 (11.9)  
 Yes (n = 109) 7 (6.4)  
Adjuvant therapy post-surgery (n = 1039)   1
 No (n = 26) 3 (11.5)  
 Yes (n = 1013) 115 (11.4)  
Chemotherapy (n = 1018)   <0.01
 No (n = 513) 43 (8.4)  
 Yes (n = 505) 73 (14.5)  
Radiotherapy (n = 998)   0.457
 No (n = 155) 15 (9.7)  
 Yes (n = 843) 99 (11.7)  
Hormone therapy (n = 1019)   0.328
 No (n = 219) 29 (13.2)  
 Yes (n = 800) 87 (10.9)  
Her2 treatment (n = 1028)   0.790
 No (n = 979) 112 (11.4)  
 Yes (n = 49) 5 (10.2)  
  1. aPercentages are computed as follows: number of women with persistent pain divided by the total number of women for each category
  2. bSLNB: sentinel lymph node biopsy. In this category only women with SLNB performed were included. ALND: axillary lymph node dissection. This category includes women with only ALND performed and women with SLNB and ALND